Parion Sciences: Shire licenses dry-eye treatment from Parion Sciences
Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.The post Shire licenses dry-eye treatment from Parion Sciences appeared first on PharmaLeaders.com.
Read full article »
Parion Sciences is a pharmaceutical firm that engages in discovery and development of new treatments for serious diseases.
Read more